Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

ABSTRACT:

SUBMITTER: Haverkos B 

PROVIDER: S-EPMC10845026 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature